-
-
This is old news and in it they framed the results in a certain way. What Allergan found is that when they used the original formulation that has the same concentration that is used for eyelash growth that it regrew some hair but not enough for them to go forward with further investigations. So they did what they had always planned on doing: increasing the concentration and changing the formulation to try to get better absorption through the thick skin on the scalp to get the active ingredients to the follicles. This is basically what they planned on doing all along.
That being said, they may still not get sufficient results. But the results of that trial that is being written about is not proof or even good evidence that it won't work. The results of the upcoming trial will be much more informative.Comment
-
Excellent news! Actavis has taken over allergan and valeant has said they will not try to compete. At the least, this should mean that we'll eventually know what the results of the clinical trials were.
This is pure speculation, but actavis spent a ton of money for allergan, 66 billion. That's 13 billion more than valeant's highest offer. Actsvis had stated that they will not cut any research and development and there's probably not much money to be gained by synergies between the two company's product lines. So they're hoping to make money the good old fashioned way: by introducing new products that will generate big sales. Granted Botox has many under exploited applications, but it's fair to assume that actavis believes allergan has some big moneymakers in the pipeline. Here's hoping it's bimatiprost for hair!Comment
-
Great! Thanks for postingComment
-
That's very good news, the results of a higher solution will be very interesting!
first growth stimulant to get close to release since minoxidil!!Comment
-
excellent news indeed - thanks for the research beetee
Care to layout the next steps and timeframe for where we go from here ?Comment
-
66 billion is a LOT of money, let's hope that figure means they are banking on some impressive results from bimatoprost.Comment
-
Btw - does anybody know if there's any evidence out there that shows bimatoprost could be more effective with something like dermaroliing?Comment
-
No problem at all, glad to see some people were interested. I was following the process of the takeover attempt a little too closely since it started last march and while there were definitely times when things did not look good, one of the best possible outcomes has occurred and I am very happy about that.
The current clinical trial is set to be completed January 2015, as indicated on their listing on clinicaltrials.gov. Allergan typically releases the results of their clinical trials within several months of their completion, and hopefully that will continue to be the case under their new owners. When allergan announced the results of the last clinical trial for this product in May 2013 they actually described the current ongoing trial as the first of two that they had planned. It's good that they are (or were) committed to fully investigating this drug's potential, and hopefully we'll hear something one way or the other about the current trial results early in the new year. As far as the second trial, i imagine it could be abandoned if the results of the current one are very good or very bad, or it may go ahead regardless.
I believe this is all there is to know at this point . While the future is still uncertain, this is a legitimate possibility and a very well established and professional company, so there's definitely reason to keep following this, if not to feel slightly hopeful.Comment
-
So, Do you think we will be able to buy bimatoprost x% from Asia markets in 2015?Comment
-
If any of you guys caught the latest bald truth radio show (it's been posted on youtube), Joe from SI called in and was very excited about bim, he seems to believe that the results of the phase IIb study is in part a big reason why allergan was bought by actavis. I agree with him, because it makes sense. If it far superior to minox, then bim will take over the market share of minox (guaranteed revenue). I personally have never used minox because the results were never that impressive, and to have to keep buying it is just ridiculous. 1/3 of the revenue coming in for allergan is from botox, and now just imagine a superior product to minoxidil that both men and women can use, it will make billions annually.
We know that bim inhibits PGD2, and according to Cotsarelis, PGD2 is what inhibits hair growth. It works amazingly on eyelashes, we know that. I think all of these developments are not coincidence, and everyone should be really excited about this.Comment
-
there was some talk here about iris pigmentation being a side effect of bimatoprost.
But now I read that they (Allergan) is actually in Phase2 trials for using Bimatoprost INSIDE the eye (through an implant , but also topically):
Allergan has reviewed data from its Phase 2 clinical trials of bimatoprost sustained-release implant for the treatment of elevated intraocular pressure and glaucoma. Patients in this trial received a bimatoprost sustained-release implant in one eye and topical bimatoprost in the contralateral eye.Comment
-
He said that he'd been hearing that the results from the phase IIb bim study had excellent results, superior to minoxidil, and would have some people coming off Propecia and minoxidil to use it instead. Spencer actually said that he'd been hearing the same as well. However, the facts are only that Johnson and Johnson was at one point looking to buy Allergan (around April), but it didn't pan out. As we know also, Valeant was trying to buy Allergan, but that didn't happen, and yesterday Actavis did.
Actavis stated in the buyout that they believe that with this combination, they'll become a top-10 pharmaceutical company. Allergan's biggest revenue maker is botox at this point, and there is nothing in their pipeline that looks like it could be extremely popular or a cash-cow. Actavis purchased the company for 13 billion more than anyone else was willing to offer at $219 a share, and the stock even jumped.
Something's going on, yet it's easy to be doubtful until those results are posted.Comment
Tweet
Comment